BST Trade Alert
BST Trade Alert: April 17, 2013
April 17, 2013 Recommendation: Buy Synergy Pharmacetucials (NASDAQ: SGYP) up to $6.00 per share. About the Company: Synergy Pharmaceuticals is a development-stage biotech with a potentially super-nova bright future. The company’s financial condition is rock solid. Their leading drug candidate might just be a better option for patients than the current FDA approved treatment. And the drug’s […]
BST Trade Alert: March 27, 2013
March 27, 2013 Recommendation: Buy AcelRx Pharmaceuticals (NASDAQ: ACRX) up to $5.65 per share. About the Company: ACRX has the all the characteristics of a biotech stock poised to skyrocket. A late-stage product candidate with blockbuster sales potential. A solid financial position. And a significant, fast-approaching catalyst. To say we’re excited about ACRX would be a huge […]
BST Trade Alert: March 7, 2013
March 7, 2013 Recommendation: Buy Halozyme Therapeutics (NASDAQ: HALO) up to $6.00 per share. About the Company: Many of you will probably have fond memories of Halozyme Therapeutics. After all, we more than doubled our money the last time we traded this exciting biotech. It was certainly one of the biggest winners we’ve had in the portfolio. […]
BST Sell Alert: February 8, 2013
February 8, 2013 Sell OPKO Health (NYSE: OPK) OPK has been red hot since early December. But now it appears the rally has ended. With the shares dropping substantially today on no news, let’s go ahead and capture our profits of 44%! Go ahead and sell OPKO Health (NYSE: OPK) as soon as possible. Congratulations on a very […]
BST Trade Alert: January 23, 2013
January 23, 2013 Recommendation: Buy MannKind (NASDAQ: MNKD) up to $2.85 per share. About the Company: MannKind is a clinical stage biotech on the brink of a major breakthrough. Phase 3 testing of their potential blockbuster product for diabetes is almost complete. And FDA approval could come as early as the first half of 2014. With such […]
BST Trade Alert: January 10, 2013
January 10, 2013 Recommendation: Buy Array BioPharma (NASDAQ: ARRY) up to $4.80 per share. About the Company: Advancing a new drug through clinical testing to FDA approval is a long and costly process. As a result, most small biotechs focus their limited resources on developing just one or two new drugs. And the vast majority of their […]
EOT Trade Alert – March 17, 2009
March 17, 2009 Trade Alert: Buy GE June 2009 $11.00 CALLS at $1.15 or better (GEWFI) Company Background: General Electric (GE) really needs no introduction. Officially, GE operates as a technology, media, and financial services company worldwide. They’re the largest industrial company in America, and they compete in hundreds of industries. They have more than 300,000 employees. […]
